Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Jun 15, 2017
- RT002 injectable 40-unit dose under study for the treatment of glabellar lines demonstrated statistical and clinical superiority over BOTOX* Cosmetic for a range of efficacy outcomes and achieved six-month duration of effect - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics...
Jun 5, 2017
- Poster on display today to be presented during late-breaking session on June 7, 2017, at 21st International Congress of Parkinson's Disease and Movement Disorders - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botu...
Jun 1, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance managem...
May 18, 2017
- Data to be presented at 21st International Congress of Parkinson's Disease and Movement Disorders, June 5-8, 2017 - - Revance to host conference call at 4:30 pm ET today - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company ...
May 9, 2017
- Completed Enrollment in SAKURA 1 & 2 Phase 3 Pivotal Trials of RT002 for Glabellar Lines - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditio...
May 1, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that it is expanding the Company's Phase 2 program investigating the use of DaxibotulinumtoxinA ...
Apr 25, 2017
- Conference Call Scheduled for Tuesday, May 9, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will ...
Mar 7, 2017
SAKURA Program Topline Results on Track to Report Fourth Quarter 2017 NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced the completion of pa...
Mar 3, 2017
- Additional Presentation Affirms Use of Patient Questionnaires in Assessing Frown Lines - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today ...
Feb 27, 2017
- Cash and investments of $185.5 million as of December 31, 2016 - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced results for the fourth ...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools